Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

BeiGene’s Brukinsa receives EC approval for marginal zone lymphoma

The BTK inhibitor was also granted an additional year of marketing protection

- PMLiVE

Gilead’s Vemlidy gets FDA approval for paediatric patients with chronic hepatitis B infection

The application was supported by positive 24-week data from a phase 2 trial

- PMLiVE

Tiziana completes enrolment of first patient cohort in MS expanded access programme

Foralumab has already demonstrated positive results in patients with non-active SPMS

- PMLiVE

NHS reports rise in prostate cancer treatments in England

Prostate Cancer UK’s risk checker has been used over a million times since its launch in February

- PMLiVE

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

The company submitted a Biologics License Application to the FDA for SRP-9001 in September

- PMLiVE

Fostering meaningful HCP engagement at congresses

By Hannah Noel

Cell and gene therapies as depicted via a DNA strand

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Avalere Health

Focusing on what matters most

Say Communications

- PMLiVE

Rare disease drug development – real-world evidence innovations with historical controls

By Will Maier

- PMLiVE

Pfizer’s maternal RSV vaccine candidate shows promise in phase 3 trial

The company stopped the trial early and plans to file for US approval by the end of 2022

- PMLiVE

GSK’s respiratory syncytial virus older adult vaccine given Priority Review by FDA

There are currently no RSV vaccines approved for older adults anywhere worldwide

- PMLiVE

EMA issues new guidance to limit use of JAK inhibitors for chronic inflammatory disorders

The guidance aim to minimise the risk of serious side effects associated with these medicines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links